Zimmer Biomet — Aug 7, 2025 release

  Warsaw, IN 46580   www.zimmerbiomet.com Exhibit 99.1     Media Investors Kristen Cardillo David DeMartino (925) 786-4913 (646) 531-6115 kristen.cardillo@zimmerbiomet.com david.demartino@zimmerbiomet.com     Kirsten Fallon Zach Weiner (781) 779-5561 (908) 591-6955 kirsten.fallon@zimmerbiomet.com zach.weiner@zimmerbiomet.com   Zimmer Biomet Announces Second Quarter 2025 Financial Results • Second quarter net sales of $2.077 billion increased 7.0% on a reported basis, 5.4% on a constant currency 1 basis and 2.8% on an organic constant currency 1 basis • Second quarter diluted earnings per share were $0.77; adjusted 1 diluted earnings per share were $2.07, an increase of 3.0% • Company tightens full-year 2025 reported, constant currency 1 and organic constant currency 1 revenue growth guidance to 6.7% - 7.7%, 6.2% - 7.2% and 3.5% - 4.5%, respectively, and increases adjusted 1 earnings per share financial guidance to $8.10 - $8.30 (WARSAW, IN) August 7, 2025 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2025. The Company reported second quarter net sales of $2.077 billion, an increase of 7.0% over the prior year period, an increase of 5.4% on a constant currency 1 basis and an increase of 2.8% on an organic constant currency basis. Net earnings for the second quarter were $152.8 million, or $411.2 million on an adjusted 1 basis. Diluted earnings per share were $0.77 for the second quarter, and adjusted 1 diluted earnings per share were $2.07, an increase of 3.0%.   1 Reconciliations of these measures to the corresponding U.S. generally accepted accounting principles measures are included in this press release.   Page 1 of 24     “Our team delivered another solid quarter of growth, as our robust new product cycle drove significant acceleration in our U.S. Hips and Knees portfolios and continued strong growth in our global S.E.T. business,” said Ivan Tornos, Chairman, President and CEO of Zimmer Biomet. “We are